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Abstract
Introduction: The human epidermal growth factor receptor 2 (HER2)-targeted therapies trastuzumab (T) and
lapatinib (L) show high efficacy in patients with HER2-positive breast cancer, but resistance is prevalent. Here we
investigate resistance mechanisms to each drug alone, or to their combination using a large panel of HER2-positive
cell lines made resistant to these drugs.
Methods: Response to L + T treatment was characterized in a panel of 13 HER2-positive cell lines to identify lines
that were de novo resistant. Acquired resistant lines were then established by long-term exposure to increasing
drug concentrations. Levels and activity of HER2 and estrogen receptor (ER) pathways were determined by qRT-
PCR, immunohistochemistry, and immunoblotting assays. Cell growth, proliferation, and apoptosis in parental cells
and resistant derivatives were assessed in response to inhibition of HER or ER pathways, either pharmacologically
(L, T, L + T, or fulvestrant) or by using siRNAs. Efficacy of combined endocrine and anti-HER2 therapies was studied
in vivo using UACC-812 xenografts.
Results: ER or its downstream products increased in four out of the five ER+/HER2+ lines, and was evident in one
of the two intrinsically resistant lines. In UACC-812 and BT474 parental and resistant derivatives, HER2 inhibition by
T reactivated HER network activity to promote resistance. T-resistant lines remained sensitive to HER2 inhibition by
either L or HER2 siRNA. With more complete HER2 blockade, resistance to L-containing regimens required the
activation of a redundant survival pathway, ER, which was up-regulated and promoted survival via various Bcl2
family members. These L- and L + T-resistant lines were responsive to fulvestrant and to ER siRNA. However, after
prolonged treatment with L, but not L + T, BT474 cells switched from depending on ER as a survival pathway, to
relying again on the HER network (increased HER2, HER3, and receptor ligands) to overcome L’s effects. The
combination of endocrine and L + T HER2-targeted therapies achieved complete tumor regression and prevented
development of resistance in UACC-812 xenografts.
Conclusions: Combined L + T treatment provides a more complete and stable inhibition of the HER network. With
sustained HER2 inhibition, ER functions as a key escape/survival pathway in ER-positive/HER2-positive cells.
Complete blockade of the HER network, together with ER inhibition, may provide optimal therapy in selected
patients.
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The human epidermal growth factor receptor 2 (HER2,
ErbB2, or HER2/neu) is a member of the HER receptor
tyrosine kinase (RTK) family, which includes three other
members: epidermal growth factor receptor (EGFR or
HER1), HER3, and HER4. Homo- and hetero-dimeriza-
tion of ligand-bound HER receptors results in activation
of multiple pathways, including the p44/42 mitogen-acti-
vated protein kinase (MAPK) and phosphatidylinositol 3-
kinase (PI3K) pathways, which regulate cell proliferation
and apoptosis [1-3]. HER2, the preferred heterodimeriza-
tion partner of the other HER receptors, does not have a
ligand and is activated by overexpression and homodi-
merization, or by ligand-mediated stimulation of another
HER receptor through heterodimerization. Approxi-
mately 20% of human breast cancers are HER2-amplified,
and overexpression correlates with aggressive tumor
behavior and poor patient outcome [4].
To date, two distinct HER2-targeting agents, trastuzu-
mab (T) and lapatinib (L), have been FDA-approved,
and both have proven efficacy in the clinical setting
[5-8]. Trastuzumab is a humanized monoclonal antibody
that binds to the extracellular domain of HER2, disrupt-
ing HER signaling and inducing antibody-dependent
cell-mediated cytotoxicity (ADCC) [9,10]. Lapatinib, a
small-molecule EGFR/HER2 dual tyrosine kinase inhibi-
tor (TKI), antagonizes the kinase activity of these recep-
tors, inhibiting phosphorylation of their substrates and
downstream signaling [11,12]. Despite their proven clini-
cal benefit, de novo a n da c q u i r e dr e s i s t a n c et ob o t hL
and T is common [13,14].
The HER signaling system has been described as a
complex, robust, and redundant biological network,
modulated by positive and negative feedback circuits [2].
These features, which protect the system from various
perturbations, can also play a key role in resistance to
drugs targeting this pathway. As such, multiple escape
mechanisms to circumvent inhibition of the HER system
have been reported to cause resistance [15,16], including
compensatory activation of the HER network [17-19] or
activation of other redundant survival pathways in the
cell [20,21]. Therefore, multi-targeted therapies might
be the optimal approach to prevent resistance in some
patients.
Multiple levels of crosstalk between estrogen receptor
(ER) and HER2 have been identified [20,21]. Our labora-
tory has previously shown that HER2 overexpression con-
tributes to de novo and acquired resistance in various
endocrine therapies [22,23]. Similarly, in the clinical set-
ting, gene amplification of HER2 is associated with resis-
tance to endocrine therapy [24-26]. Conversely, anecdotal
observations from the clinic showed up-regulation of ER
following treatment with trastuzumab in several patients
with HER2-positive tumors [27-29]. Likewise, a retrospec-
tive study suggested a greater benefit of lapatinib in those
patients with HER2-amplified tumors that are ER- and
PR-negative, compared with hormone receptor positive
patients [30]. An ER-positive/HER2-positive breast cancer
cell line, BT474, has been reported to acquire resistance to
lapatinib in vitro by up-regulating ER [20,21]. However, it
is not yet fully established if this up-regulation of ER
expression and/or activity can function as an escape
mechanism to cause resistance to HER2 targeted therapy
in other cell lines or in human breast cancer.
We and others previously hypothesized that a com-
mon mechanism of resistance to single agent anti-HER2
therapy is the incomplete blockade of the HER pathway
and its multiple potential homo- and heterodimer pairs.
We then reported that combination regimens including
L + T were superior to single agent therapy and were
capable of eradicating most HER2-positive xenografts in
vivo [24,31]. However, some tumors still developed
acquired resistance. In addition, we also showed that
optimal antitumor effect in one cell line, MCF7-HER2,
required endocrine therapy to block ER.
To further study the mechanisms of resistance to
HER2-targeted therapies, we developed a panel of over
10 different HER2-positive human breast cancer cell lines
de novo o ra c q u i r e dr e s i s t a n tt oT ,L ,o rL+T .W ef i n d
that while de novo and acquired resistance to T is asso-
ciated with reactivation of the HER2 pathway, resistance
to L or L + T is due to alternative signaling through the
ER pathway, providing clues to strategies to improve
HER2-targeted therapies in the clinic.
Materials and methods
Cell lines and reagents
The human breast cancer cell line BT474 was obtained
from AstraZeneca (Cheshire, UK) [24]. UACC-812, AU-
565, and HCC-1569 cell lines were purchased from the
American Type Culture Collection (Manassas, VA, USA).
MDA-MB-361, MDA-MB-453, HCC-1954, ZR75-30,
SKBR-3, and HCC-202 cell lines were obtained from
Dr. Joe Gray (Berkeley Lab, Berkeley, CA, USA) [32].
SUM-190 and SUM-225 cells were obtained from Dr.
Stephen Ethier (Wayne State University, Detroit, MI,
USA). MCF7-HER2 cells were established as previously
described [33]. BT474, UACC-812, MDA-MB-361, and
MDA-MB-453 cell lines were maintained in Dulbecco’s
modified Eagle medium (DMEM) supplemented with
10% heat-inactivated fetal bovine serum (FBS) and 1%
penicillin-streptomycin-glutamine (PSG). AU-565, HCC-
1569, HCC-1954, ZR75-30, and HCC-202 cells were cul-
tured in RPMI 1640 with 10% heat-inactivated FBS and
1% PSG. SKBR3 cells were grown in McCoy’s5 Aw i t h
10% heat-inactivated FBS and 1% PSG. SUM-190 cells
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lin, 1 μg/ml hydrocortisone, 5 mM ethanolamine, 10 mM
HEPES, 5 μg/ml transferrin, 10 nM triiodothyronine,
50 nM sodium selenite, and 0.5 g/l bovine serum albumin
(BSA). SUM-225 cells were grown in Ham’sF 1 2m e d i a
with 5% heat-inactivated FBS, 1% PSG, 5 μg/ml insulin,
and 1 μg/ml hydrocortisone. Cell lines resistant (R) to
HER2-targeted therapy were generated by long term cul-
ture of the cells in their original media with increasing
concentrations of trastuzumab (1 to 50 μg/ml), lapatinib
(0.1 to 1 μM), or both. For cells showing no growth inhi-
bition, the treatment duration was at least three months,
while responsive cells were cultured with their respective
treatments until growth resumed. The time to the devel-
opment of resistant growth varied from 3 to 12 months.
Trastuzumab (Herceptin) was acquired from Genen-
tech (San Francisco, CA, USA) and dissolved in sterile
distilled water. Lapatinib (Tykerb) was obtained from
GlaxoSmithKline (US headquarters in Research Triangle
Park, NC, USA) and prepared with dimethyl sulfoxide
(DMSO). Fulvestrant (Faslodex) was obtained from
AstraZeneca and prepared with ethanol.
Cell growth assay
A total of 5,000 cells/well of the parental or resistant cell
lines, cultured with their individual treatments, were pla-
ted in 96-well plates 24 hours before beginning respective
additional treatments, which consisted of 10 μg/ml tras-
tuzumab, 1 μM lapatinib, the combination of trastuzu-
mab with lapatinib, or 10
-7 M fulvestrant. Cell growth
was assessed at different time points (zero, three, six, and
nine days). Cell cultures were fixed with 4% glutaralde-
hyde and stained with 0.05% methylene blue. The dye
was subsequently extracted with 3% HCl and absorbance
measured at 655 nm. Growth fold change was deter-
mined by ((O.D. 655 nm at six days/O.D. 655 nm at zero
days) Treatment)/((O.D. 655 nm at six days/O.D. 655 nm
at zero days) Control). Growth curve and growth fold
change experiments were executed in quadruplicate.
Immunohistochemistry (IHC)
Cells were fixed in 10% neutral buffered formalin prior to
processing and paraffin embedding. Blocks were then
organized into a 3-mm core tissue array and IHC was
performed on 3-micron sections from these arrays [24].
Briefly, after deparaffinization, sections were subjected to
epitope retrieval in tris-HCl buffer (pH 9.0) and then
blocked in 3% hydrogen peroxide for 10 minutes. Slides
were incubated with primary antibody to ER (Vector
Labs, Burlingame, CA, USA), PR (Dako Cytomation, Car-
pinteria, CA, USA), or phospho-HER2-Tyr877 (Cell Sig-
naling Technology, Beverly, MA, USA), for one hour.
Immunodetection was performed with the EnVision+
System (Dako Cytomation, Carpinteria, CA, USA).
Immunoblotting assay
Cells were lysed in buffer consisting of 10% Triton
X100, 50 mM Hepes (pH 7.4), 150 mM NaCl, 1.5 mM
MgCl2, 1 mM EGTA, 100 mM NaF, 10 mM NaPPi, 10%
glycerol, 1 mM Na3VO4, and 1X protease inhibitor
cocktail (Roche Molecular Biochemicals, Indianapolis,
IN, USA). Protein lysates were collected and microcen-
trifuged at 14,000 g for 10 minutes at 4°C. Cell superna-
tants were aliquoted and stored at -80°C. Protein
concentration was measured using the Bio-Rad Protein
Assay kit (Bio-Rad Laboratories, Hercules, CA, USA)
according to the manufacturer’s directions. Equivalent
amounts of protein (25 μg) from each sample were
separated under denaturing conditions by electrophor-
esis on polyacrylamide gels containing sodium dodecyl
sulfate (SDS-PAGE) and transferred by electroblotting
onto nitrocellulose membranes (Invitrogen, Carlsbad,
CA, USA). The blots were first stained with Ponceau S
to confirm uniform loading and transfer, followed by
immunoblotting with the specific primary antibodies
according to the manufacturer’s instructions. Briefly,
blots were blocked with appropriate blocking buffer and
then reacted at 4°C with primary antibodies at dilutions
as per the manufacturer’s directions overnight. Primary
antibodies were: phospho-EGFR-Tyr1173 (Epitomics,
Burlingame, CA, USA), EGFR, phospho-HER2- Tyr877,
phospho-HER2-Tyr1221, HER2, phospho-HER3-
Tyr1289, phospho-AKT-Thr308, phospho-AKT-Ser374,
AKT, phospho-p44/42 MAPK- Thr202/Tyr204, p44/42
MAPK, b-actin, insulin-like growth factor-I receptor
(IGF1R), cleaved PARP, caveolin-1 (Cav-1), Bik (all from
Cell Signaling Technology), phospho-HER2-Tyr1248,
HER3 (from Millipore, Billerica, MA, USA), ERa (Lab
Vision, Fremont, CA, USA), progesterone receptor (PR),
Cyclin-D1, and Bcl2 (from Santa Cruz Biotechnology,
Santa Cruz, CA, USA). Blots were then incubated with a
horseradish peroxidase-linked or a fluorescently-labeled
secondary antibody for one hour, after which the labeled
proteins were visualized by chemiluminescence or by
the Odyssey Infrared Imaging System (LI-COR Bios-
ciences, Inc., Lincoln, NE, USA). Gels were produced at
least three independent times. For HER quantitation,
protein levels of three independent samples from each
resistant cell line were quantified with the Odyssey
Infrared Imaging System and normalized to b-actin
(protein levels/actin levels).
Quantitative reverse transcription-polymerase chain
reaction (qRT-PCR)
Total RNA was extracted using the RNeasy Mini kit
(Qiagen, Valencia, CA, USA) according to the manufac-
turer’s directions. For ER and PR analysis, the cDNA of
each sample was generated by Superscript II reverse
transcriptase and random hexamers (Invitrogen). Real
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SYBR Green PCR Master Mix (ABI, Carlsbad, CA,
USA), with human b-actin acting as an endogenous
control. For analysis of HER ligands and receptors, gene
expression was quantified using 100 ng of total RNA
and Taqman One-Step Universal Master Mix in each
qRT-PCR reaction, as described previously [19]. Nor-
malization of EGFR family receptor and ligand gene
expression was performed using the house-keeping gene
HP1BP3 (heterochromatin protein 1, binding protein 3).
All qRT-PCR reactions were performed in triplicate in a
standard 96-well plate format with the ABI 7500 Real-
Time qPCR System. Fold changes in mRNA expression
were determined by the 2-ΔΔCt method. Target primer
and probe sequences are available in supplemental
material (Additional file 1).
Xenograft studies
UACC-812 (ER-positive/HER2 amplified) cells were main-
tained as described in the “Cell lines and reagents” section.
Animal care was in accordance with institutional guide-
lines. UACC-812 (ER-positive/HER2 amplified) xenografts
were established in ovariectomized five- to six-week-old
athymic mice (Harlan Sprague Dawley, Madison, WI,
USA) supplemented with estrogen pellets by inoculating 5
×1 0
6 cells subcutaneously as described previously [24].
When tumors reached the size of 150 to 200 mm
3 (two to
four weeks), mice bearing the UACC-812 xenografts were
randomly allocated to eight treatment groups, including
continued estrogen (E2), E2 plus trastuzumab, E2 plus
lapatinib, E2 plus the combination regimen (L + T), estro-
gen deprivation alone (ED) by removal of the estrogen pel-
lets, ED plus trastuzumab, ED plus lapatinib, and ED plus
the combination regimen. Each treatment group contained
a minimum of 12 mice. Tumor volumes were measured
weekly as previously described [24]. Each tumor analyzed
was from a different mouse.
siRNA transfection
Pooled small-interfering RNA (siRNA) oligos targeting
EGFR, HER2, HER3, ERa, and nontargeting siRNA were
purchased (Dharmacon, Lafayette, CO, USA). Cells were
transfected with siRNA by reverse transfection per the
manufacturers’ directions. Briefly, 5,000 cells/well were
seeded into 96-well plates containing a pre-incubated
mixture of pooled siRNA oligos at 50 nM final concen-
tration and Lipofectamine RNAiMax (Invitrogen) diluted
in Opti-MEM (Invitrogen). The appropriate cell-specific
medium supplemented with the relevant, respective
drugs was added 24 hours after transfection and the
effect of siRNA was determined after an additional 48
hours. For parallel protein expression analysis, 2 Χ 10
5
cells/well were plated into six-well plates and subjected
to the transfection protocol as above.
In vitro cell proliferation assay and apoptosis assay
The cell proliferation assay was performed using the
Click-iT EdU (5-ethynyl-2’-deoxyuridine) Microplate
Assay (Invitrogen) according to the manufacturer’s direc-
tions. Following transfection with siRNA for 72 hours,
cells were cultured with 10 μM EdU for 4 hours and the
proliferation rate was analyzed by the Celigo Cytometer
(Cyntellect, San Diego, CA, USA). Change in percent cell
proliferation within parental and resistant derivatives was
calculated as ((percentage of EdU-incorporating cells
transfected with target siRNA/percentage of EdU-incor-
porating cells transfected with nontargeting siRNA) Χ
100). All measurements were performed in quadruplicate.
Apoptosis assays were performed using the Annexin
V-FITC Apoptosis Detection Kit (Abcam, Cambridge,
MA, USA). Cells transfected with siRNA for 72 hours
were incubated with Annexin V-FITC and DAPI for
30 minutes and apoptosis was analyzed by the Celigo
Cytometer (Cyntellect, San Diego, CA, USA). Change in
percent apoptosis was calculated as ((percentage of
Annexin-V positive cells transfected with target siRNA/
percentage of Annexin-V positive cells transfected with
nontargeting siRNA) Χ 100). All measurements were per-
formed in triplicate.
Statistical analysis
Experiments assessing proliferation and apoptosis of var-
ious cell-lines under various treatment conditions were
analyzed using one-way ANOVA. Data were log-trans-
formed to stabilize variances. Differences between groups
were determined by multiple comparisons using con-
trasts, and the Sidak method for P-value adjustment.
Growth curve and growth fold change data in vitro were
analyzed similarly. Error bars on plots represent +/- stan-
dard error (SE).
Xenograft tumor growth curves were constructed using
the mean tumor volume at each time point with error bars
representing the standard error of the mean. Animals that
died of other causes prior to the first animal developing a
resistant tumor were not included in the calculation of
tumor growth curves. P-values for the xenograft studies
were adjusted for multiple comparisons using the Hommel
method to control for type I error when appropriate [34].
Progression of the tumor was defined as: tumor size more
than zero and at least two consecutive measurements with
≧10% increments in tumor size. Time to progression
(PFS) is the day of the measurement on which the tumor
qualifies as a progression.
Results
Effect of combined lapatinib and trastuzumab (L+T) on a
panel of HER2-positive breast cancer cell lines
We have previously shown in two HER2-positive breast
cancer cell lines that the combination of trastuzumab
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downstream signaling and xenograft tumor growth than
either monotherapy alone [31]. To investigate this
potent combination in a broader representation of
HER2-positive breast cancer subtypes, we used a panel
of 13 different HER2-positive breast cancer cell lines
with diverse genetic profiles and biological characteris-
tics, representing both luminal and basal phenotypes
[32,35,36]. Additional file 2 shows the cell lines and
their general characteristics. Cells were treated with T
(10 μg/ml) plus L (1 μM) for 48 hrs and inhibition of
the HER pathway was evaluated by measuring phos-
phorylated EGFR, HER2, HER3, and key signal trans-
duction mediators, including AKT and p44/42 MAPK
(Figure 1A). All 13 cell lines showed significant inhibi-
tion of phosphorylated EGFR (Tyr1173), HER2
(Tyr1248), and HER3 (Tyr1289). The activity of down-
stream signaling mediators including phosphorylated
AKT and p44/42 MAPK was also dramatically decreased
in all except two lines, SKBR3 and SUM-190, which
maintained comparable levels of phosphorylated AKT
(Thr308) or showed slight reduction in phosphorylated
AKT (Ser473) before and after treatment. Thus the
combination regimen is highly effective in suppressing
the HER pathway in most HER2-overexpressing models.
Interestingly, the expression levels of total HER proteins,
especially HER3, showed significant increases after the
48-hour treatment in 10 out of 13 models.
We also assessed changes in estrogen receptor (ER) level
or its downstream gene products upon L + T treatment.
Four out of the five ER-positive cell line models, BT474,
MDA-MB-361, UACC-812, and MCF7-HER2, showed
up-regulation of ER and/or one or more ER-regulated
genes (PR, IGF1R, and Cav-1) following treatment, sug-
gesting increased classical ER signaling activity.
The induction of ER activity or increased HER3 expres-
sion could potentially function as mechanisms of de novo
resistance and, therefore, we investigated the effect of
this regimen on tumor cell proliferation by analyzing
growth inhibition after six days of treatment (Figure 1B).
Eleven out of 13 lines showed substantial growth inhibi-
tion (> 50%) with L + T treatment, including MDAMB-
453 and SUM-225 cell lines, in which HER2 is overex-
pressed but not gene-amplified. These results suggest
that the up-regulation of HER receptor expression, most
noticeably HER3, the incomplete inhibition of phos-
phorylated AKT, or the increased ER expression/signal-
ing that occurred in several cell lines were insufficient to
cause de novo resistance to short-term treatment (6 day)
with L + T.
The HCC-1569 and MDA-MB-361 cell lines, however,
demonstrated relative de novo resistance, as only modest
growth inhibition was observed in response to L + T.
The reduced sensitivity to L + T in HCC-1569 cells may
be due to the overexpression of Cyclin E as previously
described [32]. The MDA-MB-361 cell line showed
marked up-regulation of ER and PR shortly after com-
mencing treatment with L + T. Therefore, we asked
whether ER might be the mechanism for de novo resis-
tance in this model. We also investigated the effects of
T and L, alone, in this model. While cell growth was
only minimally inhibited by T, L, or the combination, it
was significantly inhibited by fulvestrant (F) (P < 0.0001,
F versus each treatment arm respectively) (Figure 1C),
indicating that these cells are highly dependent on ER
despite being amplified for HER2. These results suggest
that some ER-positive/HER2-positive breast cancer cells
might be primarily driven by ER and, thus, are intrinsi-
cally less sensitive to even potent anti-HER2 treatment.
Characterization of cell lines with acquired resistance to
T, L, and L+T
Since high ER activity can provide an escape pathway to
reduce the efficacy of and cause de novo resistance to
HER2-targeted therapies, we next asked whether up-
regulated ER expression and/or activity might cause
acquired resistance. The two cell lines (BT474 and
UACC-812) that are amplified for HER2 and that showed
up-regulated ER expression and/or activity after treat-
ment with L + T were chosen for this set of experiments,
with the parental lines demonstrating high (BT474) or
very low (UACC-812) ER expression.
To characterize the response and resistance in these
two models to different anti-HER2 therapies, parental
cells (P) and resistant derivatives (R) were treated with T,
L, or the combination regimen for six days (Figure 2A,
B). Parental UACC-812 cells are de novo resistant to T
(P = 0.2419, P: 0 versus T), but sensitive to L (P < 0.0001,
P: 0 versus L) or the combination of L + T (P < 0.0001, P:
0 versus L + T). Parental BT474 cells showed sensitivity
to all anti-HER2 therapies (P < 0.0001, P: 0 versus T, L,
or L + T,), with L-containing regimens inhibiting growth
more completely than T. In contrast, in the resistant
derivatives there were no significant differences in cell
growth in the presence or absence of the respective treat-
m e n t s .T h ec e l ll i n e sr e s i s t a n tt oT ,L ,a n dt h ec o m b i n a -
tion showed significantly higher proliferation rates than
parental cells in the presence of the respective treatments
(P < 0.0001, P:T versus TR:T, P:L versus LR:L, or P:L + T
versus LTR:L + T), suggesting that resistant derivatives
resumed growth and, indeed, had acquired resistance to
HER2-targeted therapies. Overall, the resistant cells with
or without treatment grew at a rate similar to or faster
than parental cells in the absence of treatment.
Immunohistochemistry (IHC) and qRT-PCR on
UACC-812 and BT474 parental and resistant derivatives
(Figures 2C and 3A) revealed that the low levels of ER
mRNA and protein remained low/undetectable in TR
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Figure 1 HER2-overexpressing cell lines exhibit distinct responses when treated with potent anti-HER2 therapy. (A) A panel of HER2-
overexpressing breast cancer cell lines was treated with lapatinib (1 μM) plus trastuzumab (10 μg/ml) for 48 h and whole-cell extracts were
analyzed by immunoblotting with indicated antibodies. (B) Combination therapy (trastuzumab plus lapatinib) growth response in the HER2-
overexpressing breast cancer cell line panel. Growth inhibition was determined by methylene blue assay. Shown are the percent inhibitions of
cells treated for six days normalized to non-treated cells. The experiment was performed in quadruplicate. Error bars on plots represent +/-
standard error (SE). (C) Growth curves of de novo resistant MDA-MB-361 cells treated with different target therapies/regimens for nine days:
trastuzumab (T) (10 μg/ml), lapatinib (L) (1 μM), trastuzumab plus lapatinib (L + T), or endocrine therapy, fulvestrant (F) (10
-7 M), untreated (C).
Cell numbers were quantified by absorbance at 655 nm after staining with methylene blue. Conditions were repeated in quadruplicate.
Significance between groups was determined by multiple comparisons using the Sidak method (*P < 0.0001, F versus C, T, L, or L + T).
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Figure 2 Resistant cells show greater proliferation and exhibit changes in ER and PR expression. (A) Cell proliferation assay of UACC-812 and
BT474 parental and resistant (R) cells. Cells were treated with trastuzumab (T, 10 μg/ml), lapatinib (L, 1 μM), or trastuzumab plus lapatinib (L + T). After
six days, viable cells were visualized by methylene blue staining and photographed. (B) Fold changes in cell growth of UACC-812 and BT474 parental
and resistant cells with or without the respective anti-HER2 therapies, following six days of treatment. Cell numbers were quantified by absorbance at
655 nm and normalized against Day 0. Significance between groups was determined by multiple comparisons using the Sidak method (*P < 0.0001, P:
T versus TR:T, P:L versus LR:L, or P:L + T versus LTR:L + T for both models). (C) Immunohistochemical detection of ER and PR in BT474 and UACC-812
parental and distinct resistant clones.
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tal UACC812 cells was completely lost in the TR cells.
PR mRNA was low in both parental and TR UACC-812
cells. No substantial changes in ER or PR levels were
observed in BT474 TR cells. In contrast to TR cells, LR
and LTR derivatives of both UACC-812 and BT474 dis-
played a marked increase in ER and/or PR protein
levels. PR mRNA levels were also markedly increased in
both UACC-812 and BT474 LR and LTR cells. While
ER mRNA also dramatically increased in UACC-812 LR
and LTR cells, only a modest increase in expression was
observed in BT474 parental and resistant derivatives.
These results suggest that ER expression and/or classical
transcriptional activity are correlated with acquired
resistance to both L and the L + T combination in these
HER2-positive breast cancer models.
We further determined the phosphorylation status of the
HER receptors and their downstream mediators, AKT and
p44/42-MAPK, in the parental and resistant derivatives
(Figure 3B). To evaluate the primary response of the par-
ental cell lines to anti-HER2 therapies, parental UACC-
812 and BT474 cells were treated with T (10 μg/ml), L
(1 μM), or the combination therapy for five hours. We
found that T inhibited the phosphorylation of HER3 and
partly inhibited phosphorylated EGFR in BT474 cells,
while in UACC-812 cells reduced phosphorylated HER3
but not phosphorylated EGFR was observed. This observa-
tion is consistent with published reports which suggest a
mechanism of action for trastuzumab involving disruption
of ligand-independent HER2/HER3 signaling in HER2-
positive cells [37]. Interestingly, while phosphorylated
AKT was reduced by trastuzumab in BT474 cells, it was
increased slightly in the UACC-812 line which is relatively
de novo resistant to T. However, L and L + T markedly
suppressed the entire HER pathway and the downstream
MAPK and AKT kinases in both UACC-812 and BT474
cells. Collectively, these results suggest that L-containing
regimens more effectively inhibit the HER signaling path-
way than T.
Immunoblot analysis of the parental BT474 and resis-
tant derivatives showed that cells resistant to T (TR)
maintained or reactivated the HER signaling pathway
(Figure 3B). However, cells resistant to L or L + T, in
which the HER receptor layer is more completely inhib-
ited, continued to show marked suppression of phos-
phorylated EGFR, HER2, and HER3. In contrast to TR
cells, LR and LTR cells displayed high levels of PR.
Despite a reduction in total AKT and reduced levels of
phosphorylated EGFR, HER2, and HER3, LR and LTR,
cells showed a slight increase in phosphorylated AKT.
UACC-812 resistant cells behaved in a similar manner,
where TR clones demonstrated enhanced HER signaling,
while L and the L + T resistant derivatives showed
enhanced ER activity in the wake of suppressed HER
signaling. Of note, a decrease in PTEN expression level
was observed in UACC-812 TR cells, but not in BT474
TR cells.
Growth characterization of resistant cell lines with HER2
and ER targeted therapies reveals their differential role in
resistance to trastuzumab versus lapatinib containing
regimens
To investigate whether up-regulated HER and/or ER
pathways are responsible for the proliferative and survival
stimuli of the resistant derivatives, parental and resistant
BT474 and UACC-812 lines were treated with T (10 μg/
ml), L (1 μM), the combination regimen, or the anti-
estrogen fulvestrant (F) (10
-7 M) (Figure 4A). Cell growth
was followed over nine days. Consistent with their mole-
cular profiling data, both BT474 TR and UACC-812 TR
were still dependent on HER2 and, therefore, sensitive to
L( P < 0.0001, TR + T versus TR + T + L for both mod-
e l s ) .U A C C - 8 1 2T Rs h o w e dn or e s p o n s et oF( P =
0.7004, TR + T versus TR + T + F for UACC-812 TR),
and BT474 TR sustained the same modest sensitivity to F
as parental cells. In both models, LR derivatives were also
resistant to T (P = 0.8901, LR + L versus LR + L + T for
UACC812 LR; P = 0.0788, LR + L versus LR + L + T for
BT474 LR). Conversely, however, LR and LTR cells, but
not parental cells, were highly sensitive to anti-ER ther-
apy with F. These results suggest that ER activity plays a
minimal role, if any, in TR cells where the HER pathway
remains the dominant driver of cell growth and where
TR cells are inhibited by L. In contrast, up-regulated ER
activity becomes the dominant driver in cells resistant to
L and L + T.
The effect of F on resistant cell growth became appar-
ent after Day 3 of the treatment (Figure 4A). To further
assess the mechanism by which F inhibits the growth of
the derivatives resistant to L-containing regimens, we
treated parental, LR, and LTR UACC-812 and BT474
cells with F for 24, 48 and 72 hours, and probed for levels
of ER-regulated gene expression and apoptosis molecules
(Figures 4B and 5D). ER has been shown to activate
genes associated with proliferation (for example, Cyclin
D1) and with anti-apoptosis (for example, Bcl2 and survi-
vin) in breast cancer cells [11,38]. In our study immuno-
blot analysis revealed that F induced degradation of ER in
UACC-812 and BT474 derivatives after 24 hours of treat-
ment. This led to down-regulation of Cyclin D1 and sur-
vivin in UACC-812 parental, LR, and LTR, but no
induction of the apoptotic marker cleaved PARP was
observed in parental UACC-812. In contrast, Bcl2
expression levels were increased in UACC-812 LR and
LTR cells. This induced Bcl2 expression was inhibited in
the presence of F and this was associated with induction
of cleaved PARP in these cells. In BT474 LR and LTR no
expression of Bcl2 and no significant down-regulation of
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Figure 3 Trastuzumab resistant cells maintain HER signaling. Lapatinib and combination resistant cells express up-regulated ER
activity. (A) qRT-PCR expression levels of ER and PR mRNA in UACC-812 and BT474 parental and distinct resistant clones. Data were normalized
to parental cells. (B) UACC-812 and BT474 parental cells were treated with trastuzumab (10 μg/ml), lapatinib (1 μM), or trastuzumab plus
lapatinib for five hours and harvested. Whole-cell extracts of these treatment groups and resistant derivatives were analyzed by Western blot
with the indicated antibodies.
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Figure 4 Trastuzumab resistant cells remain sensitive to lapatinib. Fulvestrant inhibits lapatinib and combination resistant cell growth.
(A) Growth curves of UACC-812 and BT474 parental and resistant cells treated with different target therapies/regimens for nine days:
trastuzumab (T) (10 μg/ml), lapatinib (L) (1 μM), trastuzumab plus lapatinib (L + T), or endocrine therapy, fulvestrant (F) (10
-7M); media of parental
cells (C). Cell numbers were quantified by absorbance at 655 nm after staining with methylene blue. Conditions were repeated in quadruplicate.
Significance between groups was determined by multiple comparisons using the Sidak method (*P < 0.0001, UACC-812 TR:T versus TR:T + L, LR:L
versus LR:L + F, or LTR:L + T versus LTR:L + T + F; BT474 TR:T versus TR:T + L, TR:T versus TR:T + F, LR:L versus LR:L + F, or LTR:L + T versus LTR:L
+T+F ) .(B) UACC-812 parental, lapatinib resistant, and combination resistant cells were treated with fulvestrant for 24, 48, 72 h and whole-cell
extracts were analyzed by Western blot with the indicated antibodies.
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Figure 5 BT474 lapatinib resistant cells with prolonged treatment reactivate HER receptor activity. (A) Growth curves of UACC-812 and
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μM), trastuzumab plus lapatinib, or endocrine therapy, fulvestrant (F) (10
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comparisons using the Sidak method (*P = 0.0008, BT474 LLR + L versus LLR + L + F, *P = 0.0044, BT474 LLR + L versus LLR + L + T; *P <
0.0001, UACC-812 LLR + L versus LLR + L + F). (B) Immunohistochemical detection of ER, PR, and phospho-HER2 (Tyr877) in BT474 late stage
lapatinib resistant cells. (C) Western blot analysis of UACC-812 and BT474 parental and resistant cell lines, including early (LR) and late (LLR) stage
lapatinib resistant cells. Whole-cell extracts were analyzed by Western blot with the indicated antibodies. (D) BT474 parental, early, late stage
lapatinib resistant, and combination (L + T) resistant cells were treated with fulvestrant for 24, 48, or 72 h and whole-cell extracts were analyzed
by Western blot with the indicated antibodies.
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Page 11 of 19Cyclin D1 was observed (Figure 5D). The proapoptotic
Bcl2 family member Bik is down-regulated by estrogen
[38] and, indeed, increased Bik and consequently cleaved
PARP were observed in BT474 parental, LR, and LTR
derivatives treated with F after 24 hours (Figure 5D). The
magnitude of F-induced apoptosis, however, was prob-
ably greater in the resistant cells, based on the growth
curve studies (Figure 4A). Interestingly, we did not
observe an increase in AXL expression (data not shown),
as previously described [20]. No inhibition of AKT activ-
ity was observed when BT474 LR or LTR were treated
with F (Figure 5D). These results suggest that F through
its antagonism of ER can overcome resistance to L-con-
taining regimens, at least part l yb yr e g u l a t i n ge x p r e s s i o n
of Bik.
The combination of endocrine and HER2-targeted therapy
leads to strong inhibition of tumor growth and complete
tumor regression in UACC-812 xenografts
To further investigate if crosstalk between ER and HER2
is a mechanism of resistance to HER2-targeted therapy in
vivo, using UACC-812 xenografts we compared the effi-
cacy of the anti-HER2 regimens alone (Figure 6A) to
block tumor growth versus their efficacy in combination
with estrogen deprivation (ED) to also inhibit the ER
pathway (Figure 6B). Anti-HER2 therapy alone (in the
presence of estrogen) (E2) was only partially effective in
slowing tumor growth and it did not lead to tumor
regression (Figure 6A), though the combination of L plus
T was superior to either monotherapy alone. The combi-
nation of ED together with anti-HER2 therapy was more
effective than ED alone (Figure 6B). The more potent L +
T combination together with ED achieved complete
tumor regression in all mice with no recurrence after 210
days. Multiple comparisons between progression-free
survivals (PFS) show that xenografts treated with the
combination of endocrine and anti-HER2 therapy exhibit
better response than with either anti-HER2 therapy alone
(Additional files 3 and 4). Groups treated with ED plus L
or ED plus the combination regimen displayed signifi-
cantly improved PFS compared with the ED group. The
combination of ED with various HER2-targeted treat-
ments also exhibited better PFS than anti-HER2 therapy
alone. These results suggest that simultaneous endocrine
therapy together with an anti-HER2 drug combination
like L + T is the most effective therapeutic regimen in
this cell line.
Switch from dependence on ER back to HER pathway
dependence after prolonged, continuous L therapy in
BT474 cells
When lapatinib-resistant BT474 cells were cultured for a
longer period in the presence of lapatinib (more than six
months) (BT474 Late LR, LLR), they acquired a more
rapid, aggressive proliferative rate compared with BT474
LR at the early phase (46-fold versus 8-fold change of
Abs 655 nm over nine days, Figure 5A). Down-regulated
ER and PR expression and up-regulated phospho-HER2
were also observed in BT474 LLR cells (Figure 5B).
Levels of phosphorylated EGFR, HER2, and HER3
increased in BT474 LLR as detected by immunoblot,
compared to LR cells. There was no change in the levels
of these proteins in long term lapatinib-treated UACC-
812 LLR cells (Figure 5C). The increased protein levels
of ER and PR observed in BT474 LR cells decreased in
BT474 LLR, as the HER pathway became active once
more. Furthermore, the extreme sensitivity to F was lost
in the LLR cells, and there was no induction of Bik or
evidence of apoptosis in BT474 LLR treated with F
(Figure 5A and 5D). These results indicate that in some
HER2-overexpressing breast cancer cells treated with L,
ER can initially function as an escape pathway to cause
resistant growth, only to be followed after more pro-
longed treatment by reactivation of the HER pathway,
which once again becomes the driver of cell growth.
Increased expression of HER2, HER3 and HER ligands
accompany BT474 LLR growth
Since BT474 LLR cells exhibited reactivated HER signaling
activity, we also measured HER ligands and receptors in
BT474 parental and resistant derivatives by qRT-PCR
(Figure 7A). EGFR was up-regulated in BT474 LR and
LTR, yet not in other derivatives. In contrast, expression
levels of HER2, HER3, EGF, TGFa, heparin-binding EGF,
betacellulin, and heregulin mRNA were all markedly
increased in BT474 LLR compared with parental cells.
Amphiregulin, which has been shown to be regulated by
classical estrogen transcriptional activity, was noticeably
increased in BT474 LR and LTR, but not in LLR in which
ER signaling was once again low.
We then asked whether parental and LR BT474 deri-
vatives expressed variable levels of HER receptor pro-
teins (Figure 7B). BT474 LLR cells expressed decreased
EGFR (P < 0.0001, P versus LLR) and HER3 (P <
0.0001, P versus LLR), but increased levels of HER2
(P = 0.0652, P versus LLR), while BT474 LR showed
similar levels of EGFR and HER2 but down-regulated
HER3 (P < 0.0001, P versus LR). BT474 LLR expressed
higher levels of HER3 compared with the LR derivative
(P < 0.0001, LR versus LLR). These data show that the
transition of LR cells (driven by ER) to LLR (driven by
HER signaling) is associated with increased levels of
HER2, HER3, and several HER ligands.
To further assess the differential roles of the HER
receptors and ER in BT474 parental and resistant deriva-
tives, EGFR, HER2, HER3, and ER were depleted indivi-
dually using small-interfering RNA (siRNA), and the
effects on proliferation, apoptosis, and signaling were
Wang et al. Breast Cancer Research 2011, 13:R121
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Page 12 of 19examined (Figure 8A, B, and Additional file 5). Parental
BT474 were extremely sensitive to HER2 knockdown,
which inhibited proliferation by 98%, induced apoptosis
by 1.8-fold, and down-regulated expression of phos-
phorylated AKT and p44/42-MAPK. Although HER3 and
ER siRNA suppressed the proliferation of parental BT474
more than 40%, no significant effects on apoptosis were
observed. Like parental BT474 cells, the TR derivative
was also extremely sensitive to HER2 siRNA, but less
responsive to HER3 knockdown (only 28% inhibition of
proliferation compared with 61% in parental cells). These
results suggest that both parental and TR BT474 cells are
highly dependent on HER2. Interestingly, knockdown of
HER receptors and ER had little or no effect on the pro-
liferation of BT474 LR and BT474 LTR, with the excep-
tion of HER3 siRNA, which inhibited the proliferation of
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Figure 6 Growth of UACC-812 xenografts treated with various anti-HER2 treatments, with or without estrogen deprivation. (A)
Treatment in the presence of estrogen supplementation, representing no endocrine therapy. Treatments included: Estrogen alone (E2) or with
lapatinib (E2 + L), trastuzumab (E2 + T), or their combination (E2 + L + T). (B) Treatments in the presence of endocrine therapy in the form of
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Page 13 of 19BT474 LTR by 60%. However, ER siRNA induced a 1.6-
fold increase in apoptosis in BT474 LR cells and a 1.4-
fold increase in apoptosis in BT474 LTR cells, while siR-
NAs against all HER receptors caused little or no
increase in apoptosis. These results are consistent with
our previous findings, demonstrating induction of
apoptosis by F but only a minimal effect on proliferation
in both BT474 LR and LTR cells. In addition, the data
also further implicate ER activity as an alternative survi-
val pathway in BT474 LR and LTR cells.
In contrast, BT474 LLR cells showed extreme sensitiv-
ity to HER2 knockdown (97% inhibition of proliferation,
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Figure 7 BT474 late stage lapatinib-resistant cells overexpress HER2 and HER ligands. (A) mRNA expression levels of HER receptors and
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Figure 8 Inhibition of HER2 restores lapatinib sensitivity in BT474 late stage lapatinib resistant cells. (A) BT474 parental and resistant
cells were treated with pooled EGFR, HER2, HER3, ER siRNA, or non-targeting control siRNA, for 72 hours. Proliferation was measured using the
Click-iT EdU (5-ethynyl-2’- deoxyuridine) Microplate Assay. Apoptosis was measured by detecting Annexin V expression. Signals were visualized
and quantitated by the Celigo cytometer (Cyntellect, San Diego, CA, USA). (B) Down-regulation of EGFR, HER2, HER3, and ER in BT474 derivatives
after siRNA treatment was detected by Western blot. Whole-cell extracts were analyzed with the indicated antibodies, including downstream
signaling. (C) Growth fold change of double dosage (2 μM) lapatinib on BT474 early and late stage-lapatinib resistant cells for six-day treatment.
Cell numbers were assessed using methylene blue and quantified by absorbance at 655 nm and normalized against Day 0. Significance between
groups was determined by multiple comparisons using the Sidak method (*P < 0.0001, LLR + L versus LLR + 2L).
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Page 15 of 191.8-fold increase in apoptosis) and HER3 knockdown
(1.67-fold increase in apoptosis). Levels of phospho
AKT and p44/42 MAPK were inhibited in BT474 LLR
cells subjected to HER2 siRNA. Furthermore, a double
dosage of lapatinib (2 μM) suppressed BT474 LLR
growth by 60% (P < 0.0001, LLR + L versus LLR + 2L),
but had no major effect on BT474 LR (Figure 8C).
Together with the results of the HER receptor quantita-
tion (Figure 7A, B), these findings indicate that ER activ-
ity provides a survival stimulus for LR BT474 cells in
the early phase of their acquired resistance; however,
with more prolonged L treatment, levels of HER2,
HER3, and multiple HER ligands increase, and the HER
pathway once again becomes the dominant driver of
proliferation and survival.
Discussion
In this report we show that a dynamic transition
between HER2 and ER activity plays a role in resistance
to L-containing regimens, while sustained HER pathway
activity is a prominent feature in TR cells. Our data sug-
gest that ER-positive/HER2-positive cells, in general,
exploit ER activity as a mechanism of de novo or
acquired resistance to effective L-containing HER2-tar-
geted regimens.
Four out of five ER-positive/HER2-positive cell lines in
our panel showed up-regulation of ER signaling following
treatment with combined L + T. However, only the
MDA- MB-361 cell line, which showed the highest
increase in ER activity upon L + T treatment, displayed a
de novo resistance phenotype. Therefore, ER in this parti-
cular cell line acts as the dominant and primary driver of
growth even before anti-HER2 therapy is initiated. The
other ER-positive lines were initially sensitive to L + T
treatment, but later ER was used as an escape pathway to
cause acquired resistance to L + T. Thus, in ER-positive/
HER2-positive breast cancer cells, either ER or HER2 can
function initially as the major promoter of proliferation
and survival. Eventually, however, with sustained, effec-
tive HER2 inhibition with L or L + T in these cell lines,
ER becomes the primary driver of cell survival resulting
in resistance to L or L + T therapy. These findings are
consistent with two recent neoadjuvant trials in HER2-
positive patients, where chemotherapy was administered
in addition to HER2-targeted therapy. These trials
demonstrated significantly lower pathological complete
response rates (pCR) in ER-positive/HER2-positive than
in ER-negative/HER2-positive tumors [39,40]. However,
neither of these trials included ER-targeted therapy. One
of these trials, which combined T plus the HER2 dimeri-
zation inhibitor pertuzumab [40], also included a group
without chemotherapy. In this group, a 6% pCR rate was
reported for the ER-positive tumors. A further recently
reported neoadjuvant trial in patients with HER2-positive
tumors, used L + T without chemotherapy but with com-
bined endocrine therapy if the tumors were ER-positive
[41]. This trial, which included patients with larger
tumors, reported a 21% pCR rate, a pCR greater than
three times that reported in the trastuzumab plus pertu-
zumab trial. Although it is difficult to compare across
trials, the lower response rate in the T plus pertuzumab
trial could be due to the failure of this regimen to target
EGFR, ER, or both. Collectively, these results suggest that
targeting the ER and HER2 pathways simultaneously in
ER-positive/HER2-positive tumors is essential for obtain-
ing optimal benefit. The results from our UACC-812
xenograft model, together with our previous findings in
the MCF7-HER2 and BT474 models [24,31], demonstrate
the capability and superiority of the potent L + T regi-
men in combination with endocrine therapy in achieving
complete tumor regression andp r e v e n t i n gt h eo n s e to f
therapeutic resistance. Therefore, these data strongly sug-
gest a potential role for this strategy in the clinic.
Unlike UACC-812 LR and LTR, which exhibit no HER
pathway activity, BT474 LR (early stage) and LTR main-
tain AKT activity, even in the presence of reduced HER
receptor activity. Previously, sustained PI3K/AKT activity
in BT474 LR clones was suggested to be regulated by
AXL, a membrane-bound receptor tyrosine kinase [20].
In addition, ER has the ability to induce the expression of
AXL, which could subsequently lead to activated AKT
[20]. However, in our early BT474 LR derivatives, AXL
expression was unchanged. When treated with F, BT474
LR displayed evidence of ER degradation, but no substan-
tial effect on AKT activity was observed. These results
suggest that other unknown mechanisms may also be
maintaining PI3K/AKT activity in these cells.
While ER activity was dominant in the LR and LTR
derivates of our cultured models, we found that HER2
activity was crucial for resistance to T, as siRNA knock-
ing down HER2 in our TR derivatives inhibited prolifera-
tion and also induced apoptosis. One of the mechanisms
of action of T is to disrupt ligand-independent HER2-
HER3 heterodimer signaling [37]. UACC-812 and BT474
TR cells maintained high levels of EGFR and HER2 but
showed decreased phosphorylated HER3, suggesting that
T still manages to effectively disrupt HER2-HER3 hetero-
dimer signaling in the resistant derivatives. Although it
has been reported that EGFR and HER3 contribute to TR
[19,42], our data demonstrate that HER2 is still required
for growth in TR cells, while knockdown of EGFR or
HER3 failed to elicit significant growth inhibition in
BT474 TR. Importantly, the contribution of changes in
antibody-dependent cell-mediated cytotoxicity (ADCC),
thought to be one partial mechanism of action of T [43],
could not be studied in our in vitro models. Therefore, in
our culture studies, the observed inhibitory effect of T in
comparison to L-containing regimens is related to the
Wang et al. Breast Cancer Research 2011, 13:R121
http://breast-cancer-research.com/content/13/6/R121
Page 16 of 19potency of this treatment directly on the HER signaling
pathway. Collectively, we did show that TR derivatives
are still dependent on the HER pathway and, therefore,
remain sensitive to L, as previously reported [44].
Of note, we did not observe up-regulation of ER
expression or signaling in the LR and LTR derivatives of
HER2-positive/ER-negative cell lines, in which the HER2
pathway remains suppressed. However, further investiga-
tion, both in vitro and in the clinical setting, is required
to evaluate whether more prolonged exposure to these
HER2-targeted therapies will reactivate the ER pathway.
We found that HER3 expression levels increased upon
commencement of HER2-targeted therapy, while HER2
phosphorylation was suppressed in most of our HER2-
overexpressing models. Previous studies have indicated
that AKT inhibition induces HER3 expression in HER2-
positive cell lines [45], and consistent with this, AKT
activity is significantly inhibited by HER2-targeted ther-
apy in the majority of the models examined. SKBR3 and
SUM-190 cells, however, maintain AKT phosphorylation
and still up-regulate HER3 expression, suggesting that
additional mechanisms must also control HER3
expression.
Reactivated HER signaling did confer resistance to L
in BT474 cells but only after the cells had experienced a
period of ER dependency. In contrast, UACC-812 LR
cells were driven by ER activity and maintained a fairly
stable phenotype even after prolonged L treatment. In
BT474 LR cells, however, a switch in dependence from
the ER to the HER2 pathway was observed during the
late phase of acquisition of LR. In this model, enhanced
ER activity reduced cell death in LR cells at the early
stage, acting as a transitional pathway. Following pro-
longed treatment with L, a significant compensatory
rearrangement of HER receptor and ligand expression
occurred, ultimately leading to up-regulated levels of
HER2, HER3, and many HER ligands. Interestingly, dou-
bling the dose of L inhibited the HER2-dependent
BT474 LLR cells, but not the ER-dependent BT474 LR
cells. A therapeutic strategy that applies high doses of L
intermittently has been shown to more effectively inhibit
tumor growth in mouse models with minimal toxicity
[46], a strategy that might be considered in the clinical
setting. Another recent report suggests that up-regulated
HER3 compensates for inhibition of L [18]. Although
HER3 knockdown has no effect on BT474 early stage
LR, HER3 siRNA induced increased apoptosis in BT474
LLR, suggesting that HER3 could contribute to LR.
Repeat biopsy of tumors from patients with LR tumors
might be helpful in differentiating those tumors with a
greater dependence on ER from those that remain
dependent on the HER pathway, thus acting as a guide
to further therapy.
Conclusions
T h ec o m p l e x i t ya n dr e d u n d a n c yo ft h eH E Rn e t w o r k
requires more complete inhibition of the HER family of
receptors with combination therapy. In cultured cells,
treatment with L is more effective than T in achieving
this inhibition, and the additive effect of the L + T com-
bination achieves a more powerful blockade of the path-
way than either therapy in isolation. In this study, we
illustrate that TR derivatives show reactivation of the
HER pathway as a mechanism of resistance. However,
with a more complete HER2 blockade, resistance to L-
containing regimens requires the activation of an alter-
native cell survival pathway. This is evident in ER-posi-
tive/HER2-positive cell lines, where up-regulation of the
ER pathway occurs in order to create an escape survival
pathway.
The findings of this study have several therapeutic
implications: (i) A more potent HER pathway inhibitor,
or a combination therapeutic strategy such as L + T,
could improve the outcome of patients with HER2-posi-
tive breast cancer. Recent reports of clinical studies
using L + T regimens support this idea. (ii) A combina-
tion of endocrine and anti-HER2 therapies given simul-
taneously might benefit ER-positive/HER2-positive
patients, including those with tumors with low ER levels
that clinically might be reported as ER-negative, espe-
cially if PR is still expressed. These ideas are currently
being tested in clinical trials.
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